



## bioMérieux's Myla<sup>®</sup> Named as Finalist in the 2012 Medical Design Excellence Awards

*Myla middleware recognized for groundbreaking innovation in In Vitro Diagnostics*

**Marcy l'Etoile, France – April 12, 2012** — A world leader in *in vitro* diagnostics, bioMérieux today announced that its [microbiology middleware, Myla<sup>®</sup>](#) has been selected as a finalist in the *In Vitro* Diagnostics category of the [Medical Design Excellence Awards \(MDEA\)](#) competition. Myla is an innovative microbiology middleware solution that offers consolidated interfacing, workflow optimization and information management. Myla is browser-based and consolidates information that can impact patient care and efficiency from ID/AST and blood culture testing in a single interface for the LIS. Users can access Myla remotely from anywhere on their network.

As the world leader in microbiology diagnostics, bioMérieux developed Myla in response to the needs of laboratories struggling to cope with increasing test volumes and resource constraints, while striving to improve patient care. Myla's intuitive dashboard allows users to rapidly gain a comprehensive view of their lab's blood culture process, perform remote validation of identification and susceptibility results, and easily generate reports. Myla provides increased traceability and visibility for technologists and microbiologists to help them take control of the testing process and improve the information available to the clinician. For instance, anyone logged into Myla is notified when blood cultures become positive, and alerts can be delivered via email or text message. Lab managers can quickly adjust their workflow around positive blood cultures and the related work-ups to deliver clinically relevant information.

*"We are honored that the MDEA judges recognize the value of Myla's features and benefits,"* said Alexandre Mérieux, Corporate Vice President of the Microbiology Unit. *"We foresee a greater integration of technology and knowledge for medicine in the future. Myla will enhance the role of the microbiology lab by consolidating data and converting it into actionable information for clinicians."*

Myla is a fundamental part of bioMérieux's FMLA™\* solutions and services developed to help customers achieve substantial productivity gains by streamlining the workflow and efficiency of the microbiology laboratory. Myla is the second product in the FMLA line to receive recognition by MDEA, after PREVI<sup>®</sup> Isola, which won its Gold Medical Design Excellence Award in 2010.

Sponsored by [Medical Device and Diagnostic Industry \(MD+DI\)](#), and organized by UBM Canon, the MDEA competition is the premier awards program for the medical technology community. It recognizes the achievements of medical device manufacturers, their suppliers, and the many people behind the scenes—engineers, scientists, designers, and clinicians—who are responsible for the groundbreaking innovations that are changing the face of healthcare. MDEA-finalist and winning entries excel in the areas of product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery.

\* Full Microbiology Lab Automation

A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, clinical practice, diagnostics, human factors, industrial design, manufacturing, and medicine. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives. The 2012 MDEA Jury selected 41 finalists in 10 medical product categories.

*MD+DI* announced the finalists in the 2012 MDEA competition in its April issue. Winning products will be announced at the MDEA Presentation Ceremony held on Wednesday, May 23, 2012.

###

### **About Medical Design Excellence Awards**

The MDEA program is presented by [UBM Canon](#), the global advanced manufacturing and MedTech authority, and by [Medical Device and Diagnostic Industry \(MD+DI\)](#), the industry's central source for late breaking news, information, and business intelligence. For more information on the Medical Design Excellence Awards, visit [www.MDEAwards.com](http://www.MDEAwards.com), or e-mail [mdea@ubm.com](mailto:mdea@ubm.com).

### ***About bioMérieux***

#### ***Advancing Diagnostics to Improve Public Health***

A world leader in the field of *in vitro* diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2011, revenues reached €1.427 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Additional information can be found at [www.biomerieux.com](http://www.biomerieux.com)

#### **Media Contacts**

##### **bioMérieux**

Koren Wolman-Tardy  
Tel: + 33 4 78 87 20 08  
[media@biomerieux.com](mailto:media@biomerieux.com)

##### **Image Sept**

Laurence Heilbronn  
Tel. : + 33 1 53 70 74 64  
[lheilbronn@image7.fr](mailto:lheilbronn@image7.fr)